BCLC stage C hepatocellular carcinoma: modern therapeutic strategies in the age of immunotherapy
Victor Lopez-Lopez,Ignacio Sánchez-Esquer,Pablo Ramírez,Ricardo Robles-Campos
DOI: https://doi.org/10.21037/jgo-24-37
2024-11-02
Journal of Gastrointestinal Oncology
Abstract:Victor Lopez-Lopez 1,2# , Ignacio Sánchez-Esquer 1,2# , Pablo Ramírez 1,2 , Ricardo Robles-Campos 1,2 1 Department of General and Digestive Surgery, Virgen de la Arrixaca University Hospital, IMIB-Arrixaca, Murcia, Spain; 2 Digestive and Endocrine Surgery and Transplantation of Abdominal Organs Research Group, Biomedical Research Institute of Murcia (IMIB), Murcia, Spain # These authors contributed equally to this work as co-first authors. Comment on: Zhang TQ, Geng ZJ, Zuo MX, et al . Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study. Signal Transduct Target Ther 2023;8:413. Keywords: Hepatocellular carcinoma (HCC); immunotherapy; hepatic arterial infusion chemotherapy (HAIC) Submitted Mar 22, 2024. Accepted for publication Sep 29, 2024. Published online Oct 29, 2024. doi: 10.21037/jgo-24-37 A recent issue of Signal Transduct Target Ther provides a thought-provoking study by Zhang and colleagues about a phase II trial about the use of camrelizumab [a programmed cell death protein 1 (PD-1) inhibitor] plus apatinib [a vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor] and hepatic artery infusion chemotherapy for hepatocellular carcinoma (HCC) in Barcelona Clinic Liver Cancer stage C (BCLC-C) (1). This trial contributes to the existing body of knowledge on treating patients with HCC in the BCLC-C category. Primary liver malignancies ranked as the world's sixth most common cancer type and held the third highest position in cancer-related deaths (2,3). HCC represents 75–85% of all liver cancer cases. The last update by the BCLC group on prognosis and treatment strategies was recently published including some new recommendations, such as the use of transarterial radioembolization (TARE) in patients with a BLCL-B (4). The current approach for HCC involves classifying patients based on tumor burden and symptoms to predict prognosis. For patients classified as BCLC-C, systemic chemotherapy is often recommended. Even so, various effective treatment options are available for eligible patients in the first, second, and further lines of therapy (5). Currently, the preferred initial treatment for unresectable or metastatic HCC is the combination of atezolizumab [an anti-programmed death-ligand 1 (PD-L1) agent] and bevacizumab [a vascular endothelial growth factor (VEGF) inhibitor] due to its enhanced survival advantages compared to sorafenib (6-8). This combination therapy shows increased PD-L1 on tumor cells and increased PD-1 expression on CD4 + cells (9). Recently, it has been demonstrated that the combination of durvalumab and tremelimumab outperforms sorafenib in response rate (20% compared to 6%) and overall survival (OS) (with a median of 16.4 vs. 13.8 months) (10). However, this combination did not show an impact on progression-free survival (PFS), with medians of 3.78 and 4.07 months respectively. Tyrosine kinase inhibitors (TKIs) like sorafenib or lenvatinib remain options when other treatments are unsuitable (5). Different strategies with anti-PD-1 antibodies have been described in the treatment of HCC patients previously treated with sorafenib. The CheckMate 040 study investigated the effectiveness and safety of various dosages of nivolumab in 262 participants, some of whom had been previously treated with sorafenib with an objective response rate (ORR) of 15% in the dose-escalation phase and 20% in the dose-expansion phase with nivolumab treatment (11). Additionally, the median OS was observed to be 15 months in the dose-expansion phase. Two phase III trials, CheckMate 459 and KEYNOTE-240 (12,13), exploring nivolumab ( vs. sorafenib) as a first-line treatment (median OS: 16.4 vs. 14.7 months) and pembrolizumab ( vs. placebo) as a second-line therapy (median OS: 13.9 vs. 10.6 months), did not demonstrate statistical significance for their primary endpoints. KEYNOTE-394 trial adds to this understanding, evaluated the effectiveness of pembrolizumab in Asian patients with advanced HCC who had prior treatment with sorafenib, compared to a placebo (14). The results indicated statistically significant enhancements in OS, as well as PFS and ORR. Another trial, KEYNOTE-524, showed that lenvatinib combined with pembrolizumab was effective and safe in treatment-naïve unresectable HCC, but this was only assessed in the first-line setting (15). CARES-310 (16), an international phase 3 trial conducted across 95 sites in 13 countries, focused on patients with unresectable or metastatic HCC without prior systemic treatment. Participants were either treated with camrelizumab intravenously every two weeks and daily oral rivoc -Abstract Truncated-
oncology,gastroenterology & hepatology